Immunocore reports prelim cash $864M, sets 2026 priorities including TEBE-AM enrollment completion in 1H 2026

Immunocore Holdings plc

Preliminary unaudited cash, cash equivalents and marketable securities ~$864M as of Dec 31, 2025.
TEBE-AM Phase 3 cutaneous melanoma trial enrollment completion expected 1H 2026; topline data as early as 2H 2026.
Phase 1/2 PRAME data expected 2H 2026: brenetafusp combos in ovarian and NSCLC, initial IMC-P115C data.
First patient in Phase 1 type 1 diabetes trial (IMC-S118AI) expected 1H 2026; autoimmune trial app for atopic dermatitis in 2H 2026.
KIMMTRAK enters 5th year post-approval; expects moderate revenue growth driven by community and global penetration.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.